Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.

Solheim JC, Reber AJ, Ashour AE, Robinson S, Futakuchi M, Kurz SG, Hood K, Fields RR, Shafer LR, Cornell D, Sutjipto S, Zurawski S, LaFace DM, Singh RK, Talmadge JE.

Cancer Gene Ther. 2007 Apr;14(4):364-71. Epub 2007 Jan 19.

PMID:
17235356
3.

Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.

Sang H, Pisarev VM, Chavez J, Robinson S, Guo Y, Hatcher L, Munger C, Talmadge CB, Solheim JC, Singh RK, Talmadge JE.

Cancer Gene Ther. 2005 Apr;12(4):427-37.

PMID:
15678151
4.

Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.

Parajuli P, Pisarev V, Sublet J, Steffel A, Varney M, Singh R, LaFace D, Talmadge JE.

Cancer Res. 2001 Nov 15;61(22):8227-34.

5.

Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy.

Wang H, Dai J, Hou S, Qian W, Li B, Ma J, Fan X, Zhao J, Yang S, Sang H, Yang Q, Wang R, Guo Y.

Cancer Gene Ther. 2005 Sep;12(9):769-77.

PMID:
15877081
6.

Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells.

McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD, Peschon JJ.

Blood. 2000 Jun 1;95(11):3489-97.

7.

Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity.

Saito T, Takayama T, Osaki T, Nagai S, Suzuki T, Sato M, Kuwano H, Tahara H.

Cancer Sci. 2008 Oct;99(10):2028-36. doi: 10.1111/j.1349-7006.2008.00907.x.

9.

Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity.

Sang H, Pisarev VM, Munger C, Robinson S, Chavez J, Hatcher L, Parajuli P, Guo Y, Talmadge JE.

Vaccine. 2003 Jun 20;21(21-22):3019-29.

PMID:
12798646
10.

Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.

Yo YT, Hsu KF, Shieh GS, Lo CW, Chang CC, Wu CL, Shiau AL.

Cancer Gene Ther. 2007 Nov;14(11):904-17. Epub 2007 Aug 17.

PMID:
17704754
11.

Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.

Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schellhammer PF, Somers KD.

Cancer Immunol Immunother. 2003 Sep;52(9):535-45.

PMID:
14627125
12.

Cancer gene therapy using in vivo electroporation of Flt3-ligand.

Shimao K, Takayama T, Enomoto K, Saito T, Nagai S, Miyazaki J, Ogawa K, Tahara H.

Int J Oncol. 2005 Aug;27(2):457-63.

PMID:
16010428
13.

Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.

Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr, Schellhammer PF, Glass WF, Somers KD.

J Immunother. 2004 Jan-Feb;27(1):13-26.

PMID:
14676630
14.

Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.

Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Miyagi T, Jinushi M, Sakamori R, Kohga K, Uemura A, Ohkawa K, Storkus WJ, Hayashi N.

Gene Ther. 2007 Jun;14(11):863-71. Epub 2007 Mar 8.

PMID:
17344900
15.

Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment.

Matsumura N, Mandai M, Hamanishi J, Yamaguchi K, Fukuhara K, Yagi H, Higuchi T, Takakura K, Fujii S.

Oncol Rep. 2008 Feb;19(2):505-15.

PMID:
18202801
16.

Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.

Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE.

Int Immunopharmacol. 2009 Jul;9(7-8):937-48. doi: 10.1016/j.intimp.2009.03.021. Epub 2009 Apr 9.

PMID:
19362167
17.

Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.

Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, Singh RK, Hoke TA, Talmadge JE.

Cancer Immunol Immunother. 2010 Jan;59(1):47-62. doi: 10.1007/s00262-009-0719-2. Epub 2009 May 18.

PMID:
19449184
18.

The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector.

Zurkova K, Babiarova K, Hainz P, Krystofova J, Kutinova L, Otahal P, Nemeckova S.

Oncol Rep. 2009 May;21(5):1335-43.

PMID:
19360312
19.

Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment.

Swee LK, Bosco N, Malissen B, Ceredig R, Rolink A.

Blood. 2009 Jun 18;113(25):6277-87. doi: 10.1182/blood-2008-06-161026. Epub 2009 Feb 10.

20.

Supplemental Content

Support Center